BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890-897. [PMID: 17632041 DOI: 10.1016/j.cgh.2007.05.004] [Cited by in Crossref: 194] [Cited by in F6Publishing: 182] [Article Influence: 12.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468-476. [PMID: 25187919 DOI: 10.1002/hep.27034] [Cited by in Crossref: 121] [Cited by in F6Publishing: 75] [Article Influence: 15.1] [Reference Citation Analysis]
2 Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 2014;7:309-20. [DOI: 10.1586/eri.09.10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
3 Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341-353. [PMID: 22326017 DOI: 10.1016/s1473-3099(11)70314-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
4 Vermehren J, Kau A, Zeuzem S. Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment. Curr Hepatitis Rep 2010;9:53-9. [DOI: 10.1007/s11901-010-0036-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Jain P. DNA-guided hepatitis B treatment: Viral load is insufficient with few exceptions. World J Gastroenterol 2009; 15(12): 1530-1531 [PMID: 19322931 DOI: 10.3748/wjg.15.1530] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH. Hepatitis B virus infection and renal transplantation. World J Gastroenterol 2010; 16(31): 3878-3887 [PMID: 20712048 DOI: 10.3748/wjg.v16.i31.3878] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
7 Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66:335-343. [PMID: 28012257 DOI: 10.1002/hep.28916] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
8 Ismail AM, Sivakumar J, Anantharam R, Dayalan S, Samuel P, Fletcher GJ, Gnanamony M, Abraham P. Performance characteristics and comparison of Abbott and artus real-time systems for hepatitis B virus DNA quantification. J Clin Microbiol. 2011;49:3215-3221. [PMID: 21795507 DOI: 10.1128/jcm.00915-11] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 You H, Jia J. Telbivudine treatment in chronic hepatitis B: experience from China. J Viral Hepat 2013;20 Suppl 1:3-8. [PMID: 23458519 DOI: 10.1111/jvh.12058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11:869-892, ix. [PMID: 17981233 DOI: 10.1016/j.cld.2007.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
11 Chen CH, Hu TH, Hung CH, Wang JH, Lu SN, Lee CM. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. J Viral Hepat 2014;21:e55-64. [PMID: 24766327 DOI: 10.1111/jvh.12239] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
12 Chotiyaputta W, Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62. [DOI: 10.1038/nrgastro.2009.107] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
13 Peng CY, Hsieh TC, Hsieh TY, Tseng KC, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC, Kao JH. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. J Formos Med Assoc 2015;114:308-13. [PMID: 24315616 DOI: 10.1016/j.jfma.2013.10.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
14 Lee HJ, Eun JR, Lee CH, Hwang JS, Suh JI, Kim BS, Jang BK. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases]. Korean J Hepatol. 2009;15:179-192. [PMID: 19581770 DOI: 10.3350/kjhep.2009.15.2.179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
15 Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
16 Lim Y, Lee YS, Gwak G, Byun KS, Kim YJ, Choi J, An J, Lee HC, Yoo BC, Kwon SY. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology 2017;66:772-83. [DOI: 10.1002/hep.29187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
17 Tsai M, Yu H, Hung C, Lee C, Chiu K, Lin M, Tseng P, Chang K, Yen Y, Chen C, Hu T. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis: Telbivudine and entecavir on naïve compensated cirrhosis. J Gastroenterol Hepatol 2014;29:568-75. [DOI: 10.1111/jgh.12436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
18 Mello FC, Fernandes CA, Gomes Sde A. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. Mem Inst Oswaldo Cruz. 2012;107:317-325. [PMID: 22510826 DOI: 10.1590/S0074-02762012000300005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-10. [PMID: 19467727 DOI: 10.1016/j.jhep.2009.04.003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 6.4] [Reference Citation Analysis]
20 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008;28:167-177. [PMID: 18466358 DOI: 10.1111/j.1365-2036.2008.03731.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
21 Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int. 2015;35 Suppl 1:82-90. [PMID: 25529092 DOI: 10.1111/liv.12735] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
22 Jang W, Yu SI, Sinn DH, Park SH, Park H, Park JY, Jeon TJ, Oh TH, Shin WC, Choi WC. Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos(t)ide analogue. Clin Res Hepatol Gastroenterol 2014;38:195-200. [PMID: 24231289 DOI: 10.1016/j.clinre.2013.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
23 Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med 2014;8:135-44. [PMID: 24810645 DOI: 10.1007/s11684-014-0331-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
24 Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56 Suppl 1:S112-S122. [PMID: 22300461 DOI: 10.1016/s0168-8278(12)60012-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
25 Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-infective Therapy 2014;7:259-68. [DOI: 10.1586/eri.09.6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
26 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. World J Gastroenterol 2015; 21(43): 12421-12429 [PMID: 26604649 DOI: 10.3748/wjg.v21.i43.12421] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Lai M, Liaw Y. Chronic Hepatitis B: Past, Present, and Future. Clinics in Liver Disease 2010;14:531-46. [DOI: 10.1016/j.cld.2010.05.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
29 Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011;11:285-300. [PMID: 21204745 DOI: 10.1517/14712598.2011.546340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
30 Lu HY, Zhuang LW, Yu YY, Si CW. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2010;17 Suppl 1:59-65. [PMID: 20586935 DOI: 10.1111/j.1365-2893.2010.01272.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
31 Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011;16:713-29. [PMID: 22195605 DOI: 10.1517/14728214.2011.646260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
32 Hsu CW, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24. BMC Gastroenterol 2012;12:178. [PMID: 23234302 DOI: 10.1186/1471-230X-12-178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
33 Yin Y, Zhang P, Tan Z, Zhou J, Wu L, Hou H. The Association of Pre-S/S Gene Mutations and Hepatitis B Virus Vertical Transmission. Hepat Mon 2016;16:e32160. [PMID: 27226799 DOI: 10.5812/hepatmon.32160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
34 Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8:e54279. [PMID: 23390496 DOI: 10.1371/journal.pone.0054279] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
35 Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6987-6995 [PMID: 23322998 DOI: 10.3748/wjg.v18.i47.6987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
36 Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011;56:3143-3162. [PMID: 21935699 DOI: 10.1007/s10620-011-1841-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
37 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
38 Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther. 2011;34:972-981. [PMID: 21883327 DOI: 10.1111/j.1365-2036.2011.04833.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
39 Rustgi V, Carriero D, Bachtold M, Zeldin G. Update on Chronic Hepatitis B. The Journal for Nurse Practitioners 2010;6:631-9. [DOI: 10.1016/j.nurpra.2010.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Planas R, Morillas RM. Tratamiento de la infección por el virus de la hepatitis B. Estado actual y perspectivas. Gastroenterología y Hepatología 2008;31:349-55. [DOI: 10.1157/13123603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Nash KL, Alexander GJ. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:444-8. [PMID: 18485825 DOI: 10.1016/S1473-3099(08)70102-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS. HBV DNA loss within 24 weeks predicts late viral breakthrough in chronic hepatitis B. Korean J Gastroenterol 2011;58:25-30. [PMID: 21778800 DOI: 10.4166/kjg.2011.58.1.25] [Reference Citation Analysis]
43 Chan HL, Wong VW, Wong GL, Chim AM, Chan H, Sung JJ. Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. Clinical Gastroenterology and Hepatology 2008;6:1022-6. [DOI: 10.1016/j.cgh.2008.03.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
44 Rashed-Ul Islam SM, Jahan M, Tabassum S. Evaluation of a Rapid One-step Real-time PCR Method as a High-throughput Screening for Quantification of Hepatitis B Virus DNA in a Resource-limited Setting. Euroasian J Hepatogastroenterol 2015;5:11-5. [PMID: 29201678 DOI: 10.5005/jp-journals-10018-1121] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Lo AO, Wong VW, Wong GL, Chan HL, Dan Y. Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2015;13:377-385.e5. [DOI: 10.1016/j.cgh.2014.06.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
46 Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449-454. [PMID: 20646776 DOI: 10.1016/j.jhep.2010.03.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
47 Gu EL, Yu YQ, Wang JL, Ji YY, Ma XY, Xie Q, Pan HY, Wu SM, Li J, Chen CW, Xu XW, Wang YE, Yao GB, Wang H, Zhang WH. Response-guided treatment of cirrhotic chronic hepatitis B patients: Multicenter prospective study. World J Gastroenterol 2015; 21(2): 653-660 [PMID: 25605989 DOI: 10.3748/wjg.v21.i2.653] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
48 Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Marcos M, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D. A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit. J Clin Virol 2017;95:76-83. [PMID: 28892764 DOI: 10.1016/j.jcv.2017.08.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
49 Fan HB, Guo YB, Zhu YF, Chen AS, Zhou MX, Li Z, Xu LT, Ma XJ, Yan FM. Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection. Hepat Mon. 2012;12:333-338. [PMID: 22783345 DOI: 10.5812/hepatmon.6173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
50 Montineri A, Nigro L, Chiarenza A, Larocca L, La Rosa R, Iacobello C, Di Raimondo F, Fatuzzo F. Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 2010;51:554-7. [DOI: 10.3109/10428190903553961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Yu HC, Lin KH, Hsu PI, Tsay FW, Wang HM, Tsai TJ, Lai KH. Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. Clin Ther. 2013;35:1386-1399. [PMID: 24054706 DOI: 10.1016/j.clinthera.2013.07.329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
52 Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3 Suppl 1:16-23. [PMID: 19669242 DOI: 10.1007/s12072-009-9143-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
53 Rodríguez M, González-Diéguez ML. [Clinical management of patients with chronic hepatitis B virus infection]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:56-65. [PMID: 19100232 DOI: 10.1016/s0213-005x(08)76520-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Lim SG. Telbivudine: a hepatitis B-specific antiviral. Expert Rev Clin Pharmacol 2008;1:217-29. [PMID: 24422647 DOI: 10.1586/17512433.1.2.217] [Reference Citation Analysis]
55 Dan YY, Wong JB, Hamid SS, Han KH, Jia JD, Liu CJ, Piratvisuth T, Lok AS, Lim SG. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatol Int. 2014;8:382-394. [PMID: 26202640 DOI: 10.1007/s12072-014-9549-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
56 Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother. 2012;67:696-699. [PMID: 22174039 DOI: 10.1093/jac/dkr495] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
57 Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections: Facing antiviral drug resistance. Journal of Gastroenterology and Hepatology 2012;27:1432-40. [DOI: 10.1111/j.1440-1746.2012.07198.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. J Viral Hepat. 2012;19:e41-e47. [PMID: 22239525 DOI: 10.1111/j.1365-2893.2011.01509.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
59 Liu X, Shen Z, Zhang H, Liang J, Lin H. Interleukin-21 Is Associated with Early Antiviral Response in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. J Interferon Cytokine Res 2016;36:367-73. [PMID: 26840345 DOI: 10.1089/jir.2015.0129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
60 Chen L, Zhang Q, Yu DM, Wan MB, Zhang XX. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol. 2009;50:895-905. [PMID: 19304333 DOI: 10.1016/j.jhep.2008.12.018] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
61 Lee KS, Kim DJ; Guideline Committee of the Korean Association for the Study of the Liver. Management of Chronic Hepatitis B. Korean J Hepatol 2007;13:447. [DOI: 10.3350/kjhep.2007.13.4.447] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
62 Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther. 2012;35:1326-1335. [PMID: 22506552 DOI: 10.1111/j.1365-2036.2012.05098.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
63 Wu I, Shiffman M, Tong M, Marcellin P, Mondou E, Frederick D, Snow‐lampart A, Sorbel J, Rousseau F, Chang T. Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants. CLIN INFECT DIS 2008;47:1305-11. [DOI: 10.1086/592570] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
64 Pan HY, Pan HY, Chen L, Yang DH, Huang HJ, Tong YX, Chen CR, Yan J. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients. Clin Microbiol Infect 2015;21:1123.e1-9. [PMID: 26253290 DOI: 10.1016/j.cmi.2015.07.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
65 Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59:1283-1292. [PMID: 24382690 DOI: 10.1002/hep.26885] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
66 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
67 Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, Han KH, Chon CY, Park JY. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int 2012;32:1179-85. [DOI: 10.1111/j.1478-3231.2012.02793.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
68 Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, Janssen HL. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat 2009;16:113-20. [PMID: 19175883 DOI: 10.1111/j.1365-2893.2008.01053.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
69 Rijckborst V, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther. 2011;33:501-513. [PMID: 21198707 DOI: 10.1111/j.1365-2036.2010.04555.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
70 Fung J, Lai CL, Yuen MF. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Rev Anti Infect Ther. 2010;8:717-726. [PMID: 20521898 DOI: 10.1586/eri.10.45] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
71 Yang JF, Lin YY, Huang JF, Liu SF, Chu PY, Hsieh MY, Lin ZY, Chen SC, Wang LY, Dai CY. Comparison of clinical application of the Abbott HBV PCR kit and the VERSANT HBV DNA 3.0 test to measure serum hepatitis B virus DNA in Taiwanese patients. Kaohsiung J Med Sci. 2009;25:413-422. [PMID: 19605335 DOI: 10.1016/s1607-551x(09)70536-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
72 Chen S, Wu J, Gu E, Shen Y, Wang F, Zhang W. Evaluation of the dynamic pattern of viral evolution in patients with virological breakthrough during treatment with nucleoside/nucleotide analogs by ultra‑deep pyrosequencing. Mol Med Rep 2016;13:651-60. [PMID: 26648309 DOI: 10.3892/mmr.2015.4577] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
73 Wang J, Ma YJ, Tang H. Optimal strategy for antiviral therapy of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2010; 18(28): 2985-2991 [DOI: 10.11569/wcjd.v18.i28.2985] [Reference Citation Analysis]
74 Li X, Li F, Zhang Y, Kang Y, Yu J, Yang F, Liu H, Qin Y, Huang Y, Mao R, Zhang J. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity. Biochem Biophys Res Commun 2015;464:1185-91. [PMID: 26212437 DOI: 10.1016/j.bbrc.2015.07.101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
75 Zhou P, Yang F, Wang J, Mao R, Qi X, Huang Y, Zhang J. Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients. Medicine (Baltimore) 2015;94:e730. [PMID: 25929904 DOI: 10.1097/MD.0000000000000730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
76 Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int. 2011;16. [PMID: 21744310 DOI: 10.1007/s12072-011-9295-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
77 Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10. [PMID: 19669367 DOI: 10.1007/s12072-008-9108-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
78 Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, Lee SH, Hwang JH, Jeong SH, Kim N. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol. 2011;17:268-273. [PMID: 22310791 DOI: 10.3350/kjhep.2011.17.4.268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
79 Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat. 2009;16:149-155. [PMID: 19236641 DOI: 10.1111/j.1365-2893.2009.01078.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
80 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 7.6] [Reference Citation Analysis]
81 Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013;10:427-433. [PMID: 23471472 DOI: 10.7150/ijms.5472] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
82 Law ST, Lee MK, Lee AS, Tung Y, Li KK. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy. J Dig Dis 2016;17:325-33. [PMID: 27085094 DOI: 10.1111/1751-2980.12349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
83 Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177. [PMID: 19852523 DOI: 10.2165/11319850-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
84 Choi MS, Yoo BC. Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver 2010;4:15-24. [PMID: 20479908 DOI: 10.5009/gnl.2010.4.1.15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
85 Suárez E, Gila A, Figueruela B, Chueca N, Muñoz Rueda P, Puche B, Fraga E, García F, Martín JM, Andrade RJ, Nogales C, Romero-Gómez M, Salmerón J. [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. Gastroenterol Hepatol 2011;34:69-74. [PMID: 21334762 DOI: 10.1016/j.gastrohep.2010.11.003] [Reference Citation Analysis]
86 Piratvisuth T, Komolmit P, Chan HL, Tanwandee T, Sukeepaisarnjaroen W, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Manns M, Uddin A, Dong Y, Trylesinski A. Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. Drugs Context 2016;5:212294. [PMID: 27403192 DOI: 10.7573/dic.212294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Min L, Chen X, Ye Y, Zhang Q, Ru S, Li X. Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evid Based Complement Alternat Med 2013;2013:767290. [PMID: 24282437 DOI: 10.1155/2013/767290] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
88 Einollahi B. Therapy for HBV Infection in Hemodialysis Patients: Is it Possible? Hepat Mon 2012;12:153-7. [PMID: 22550522 DOI: 10.5812/hepatmon.834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
89 Zhao WF, Shao YL, Chen LY, Wu JH, Zhu YL, Gan JH, Xiong H. Establishment of a new quantitative detection approach to adefovir-resistant HBV and its clinical application. World J Gastroenterol 2010; 16(10): 1267-1273 [PMID: 20222172 DOI: 10.3748/wjg.v16.i10.1267] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Soriano V, Mcmahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Research 2013;100:435-8. [DOI: 10.1016/j.antiviral.2013.08.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
91 Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clinical Gastroenterology and Hepatology 2008;6:1315-41. [DOI: 10.1016/j.cgh.2008.08.021] [Cited by in Crossref: 315] [Cited by in F6Publishing: 289] [Article Influence: 22.5] [Reference Citation Analysis]
92 Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008;22:1399-1410. [PMID: 18614862 DOI: 10.1097/qad.0b013e3282f8b46f] [Cited by in Crossref: 114] [Cited by in F6Publishing: 42] [Article Influence: 8.1] [Reference Citation Analysis]
93 Calleja JL, Peñas B. [Entecavir]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:39-48. [PMID: 19100230 DOI: 10.1016/s0213-005x(08)76518-2] [Reference Citation Analysis]
94 Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol. 2011;55:522-528. [PMID: 21147187 DOI: 10.1016/j.jhep.2010.11.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
95 Choi K, Lee HM, Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. [Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B]. Korean J Gastroenterol 2015;65:35-42. [PMID: 25603852 DOI: 10.4166/kjg.2015.65.1.35] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
96 Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World J Gastroenterol 2012; 18(43): 6290-6301 [PMID: 23180951 DOI: 10.3748/wjg.v18.i43.6290] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
97 Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol. 2008;1:61-75. [PMID: 21180515 DOI: 10.1177/1756283x08093944] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
98 Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2011;12:2025-2040. [PMID: 21682661 DOI: 10.1517/14656566.2011.590474] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
99 Kumar M, Sarin SK. Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther. 2008;27:1187-1209. [PMID: 18373730 DOI: 10.1111/j.1365-2036.2008.03695.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
100 Pan CQ, Hu K, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir: Tenofovir for entecavir suboptimal response. Journal of Viral Hepatitis 2012;19:213-9. [DOI: 10.1111/j.1365-2893.2011.01533.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
101 Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842. [PMID: 20872709 DOI: 10.1002/jmv.21898] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
102 Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009;49:S112-S121. [PMID: 19399795 DOI: 10.1002/hep.22920] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 5.9] [Reference Citation Analysis]
103 Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepat. 2012;19:724-731. [PMID: 22967104 DOI: 10.1111/j.1365-2893.2012.01599.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
104 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
105 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
106 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol 2012; 18(48): 7149-7157 [PMID: 23326119 DOI: 10.3748/wjg.v18.i48.7149] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
107 Reijnders JG, LA Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist 2009;2:13-26. [PMID: 21694884 DOI: 10.2147/idr.s3918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 2013;33:116-24. [DOI: 10.1111/liv.12069] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
109 Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009;49:S166-73. [PMID: 19399793 DOI: 10.1002/hep.22899] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
110 Charuworn P, Cheung R. Diagnostic markers for hepatitis virus infection. Expert Opinion on Medical Diagnostics 2008;2:303-14. [DOI: 10.1517/17530059.2.3.303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Holness G, Carriero DC, Dieterich DT. Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 2014;3:693-9. [DOI: 10.1586/egh.09.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Gaeta GB. Telbivudine: Taking into account baseline and on-therapy predictors. J Hepatol 2008;49:874-5. [PMID: 18814930 DOI: 10.1016/j.jhep.2008.08.008] [Reference Citation Analysis]
113 Zheng M, Shi K, Dai Z, Ye C, Chen Y. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clinical Therapeutics 2010;32:649-58. [DOI: 10.1016/j.clinthera.2010.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
114 Lui YY, Chan HL. A review of telbivudine for the management of chronic hepatitis B virus infection. Expert Opinion on Drug Metabolism & Toxicology 2008;4:1351-61. [DOI: 10.1517/17425255.4.10.1351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
115 Nguyen NH, Nguyen V, Trinh HN, Lin B, Nguyen MH. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. Clin Gastroenterol Hepatol 2013;11:565-71. [PMID: 23333662 DOI: 10.1016/j.cgh.2012.12.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
116 Lei RX, Shi H, Peng XM, Zhu YH, Cheng J, Chen GH. Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection. Hepatology. 2009;50:763-771. [PMID: 19492430 DOI: 10.1002/hep.23062] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
117 Lin TF, Hsu PI, Lin KH, Tsay FW, Tsai TJ, Chen YH, Yu HC. Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy. Gastroenterol Res Pract 2017;2017:4192169. [PMID: 28757867 DOI: 10.1155/2017/4192169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int. 2009;29 Suppl 1:108-115. [PMID: 19207973 DOI: 10.1111/j.1478-3231.2008.01939.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
119 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
120 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Wang CC, Lin CL, Hsieh TY, Tseng KC, Peng CY, Su TH, Yang SS, Hsu YC, Chen TM, Kao JH. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. Hepatol Int 2016;10:294-301. [PMID: 26399763 DOI: 10.1007/s12072-015-9662-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20:O90-O100. [PMID: 23659493 DOI: 10.1111/1469-0691.12220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
123 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
124 Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
125 Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013;68:2154-2163. [PMID: 23620466 DOI: 10.1093/jac/dkt147] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
126 Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ. Genotypic resistance to entecavir in chronic hepatitis B patients. Korean J Hepatol 2010;16:147. [DOI: 10.3350/kjhep.2010.16.2.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
127 Wang LC, Chen EQ, Cao J, Liu L, Wang JR, Lei BJ, Tang H. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. J Viral Hepat. 2010;17:178-184. [PMID: 19656287 DOI: 10.1111/j.1365-2893.2009.01164.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
128 Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig 2017;37:233-47. [PMID: 27928739 DOI: 10.1007/s40261-016-0486-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
129 Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH. Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS One 2020;15:e0237586. [PMID: 32785260 DOI: 10.1371/journal.pone.0237586] [Reference Citation Analysis]
130 Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, Chutaputti A, Rasenack J, Hou J, O’Brien C. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11-20. [PMID: 19345439 DOI: 10.1016/j.jhep.2008.12.019] [Cited by in Crossref: 154] [Cited by in F6Publishing: 154] [Article Influence: 11.8] [Reference Citation Analysis]
131 Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2009;7:1053-62. [PMID: 19883325 DOI: 10.1586/eri.09.75] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
132 Kim YJ, Paik SW, Sinn DH, Gwak G, Choi MS, Lee JH, Koh KC, Yoo BC. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance: Adefovir add-on in lamivudine-resistance. Journal of Gastroenterology and Hepatology 2012;27:1454-60. [DOI: 10.1111/j.1440-1746.2011.07050.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
133 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
134 Jia JD, Hou JL, Yin YK, Tan DM, Xu D, Niu JQ, Zhou XQ, Wang YM, Zhu LM, Chen CW, He YW, Ren H, Wan MB, Wu SM, Wang QH, Wei L, Bao W, Dong Y, Trylesinski A. Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. Hepatol Int 2014;8:72-82. [PMID: 26202408 DOI: 10.1007/s12072-013-9488-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
135 Kumar M, Sarin SK. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2014;2:465-95. [DOI: 10.1586/17474124.2.4.465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology. 2009;49:1158-1165. [PMID: 19263474 DOI: 10.1002/hep.22790] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 7.2] [Reference Citation Analysis]
137 Iser DM, Lewin SR. Future directions in the treatment of HIV-HBV coinfection. HIV Ther 2009;3:405-15. [PMID: 20161405 DOI: 10.2217/hiv.09.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
138 Zhang YR, Li B, Wang CX, Zhou N, Qi W, Li XL, Wu LY, Wei SF, Zhang YD. Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugs. Braz J Med Biol Res 2017;50:e5796. [PMID: 28273209 DOI: 10.1590/1414-431X20165796] [Reference Citation Analysis]
139 Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. J Clin Virol 2015;72:88-94. [PMID: 26476325 DOI: 10.1016/j.jcv.2015.09.012] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
140 Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608.e1-e2. [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063] [Cited by in Crossref: 468] [Cited by in F6Publishing: 443] [Article Influence: 36.0] [Reference Citation Analysis]
141 Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, Keeffe EB, Nguyen MH. High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. Journal of Clinical Gastroenterology 2011;45:900-5. [DOI: 10.1097/mcg.0b013e318224d64f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
142 Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. Expert Opin Drug Saf. 2011;10:809-818. [PMID: 21671843 DOI: 10.1517/14740338.2011.593507] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
143 Huang YW, Chayama K, Kao JH, Yang SS. Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. Hepatobiliary Surg Nutr 2015;4:197-202. [PMID: 26151059 DOI: 10.3978/j.issn.2304-3881.2014.11.08] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
144 Ahn SH, Chun JY, Shin SK, Park JY, Yoo W, Hong SP, Kim SO, Han KH. Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B. Clin Mol Hepatol 2013;19:399-408. [PMID: 24459645 DOI: 10.3350/cmh.2013.19.4.399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Ye YA, Tian DL, Jiang J, Li J, Chen JJ, Li ZH, Ma WG, Zhao YM, Wang RB, Yang SZ, Shao FZ, Ji G, Zhou DQ, Liu TJ, Cheng DS, Zhang W, Sun KW, Wang YF, Min LQ, Li XK. Effect of Shuanghu Qinggan Granule () and Yigan Yiqi Jieyu Granule () plus lamivudine on chronic hepatitis B patients: A randomized double-blind placebo-controlled trial. Chin J Integr Med 2016. [PMID: 27933509 DOI: 10.1007/s11655-016-2519-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
146 Zhang S, Ristau JT, Trinh HN, Garcia RT, Nguyen HA, Nguyen MH. Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study. Dig Dis Sci 2012;57:1373-83. [PMID: 22466077 DOI: 10.1007/s10620-012-2137-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
147 Scott JD, Mcmahon B. Role of combination therapy in chronic hepatitis B. Curr Gastroenterol Rep 2009;11:28-36. [DOI: 10.1007/s11894-009-0005-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
148 Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2014;59:1303-1310. [PMID: 24170683 DOI: 10.1002/hep.26910] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
149 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
150 Takayama H, Komura T, Kagaya T, Sugimoto S, Orita N, Asahina Y, Nishikawa M, Ohta H, Kaneko S, Unoura M. Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B. Can J Gastroenterol Hepatol 2021;2021:3259833. [PMID: 34422709 DOI: 10.1155/2021/3259833] [Reference Citation Analysis]
151 Sitnik R, Paes A, Mangueira CP, Pinho JR. A real-time quantitative assay for hepatitis B DNA virus (HBV) developed to detect all HBV genotypes. Rev Inst Med Trop Sao Paulo 2010;52:119-24. [PMID: 20602019 DOI: 10.1590/s0036-46652010000300001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
152 Silva LCD, Nova MLD, Ono-nita SK, Pinho JRR, Sitnik R, Santos VAD, Carrilho FJ. Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B. Rev Inst Med trop S Paulo 2009;51:261-8. [DOI: 10.1590/s0036-46652009000500005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
153 Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Mancon A, Marcos MA, Sauné K, O Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D. A European multicenter study on the analytical performance of the VERIS HBV assay. J Clin Virol 2018;99-100:50-6. [PMID: 29328964 DOI: 10.1016/j.jcv.2017.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
154 Jacobson IM. Combination therapy for chronic hepatitis B: ready for prime time? J Hepatol 2008;48:687-91. [PMID: 18331764 DOI: 10.1016/j.jhep.2008.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
155 Gonen C, Gunduz F, Doganay L, Enc FY, Yegin EG, Ahishali E, Erdem E, Sokmen M, Tuncer I, Ozdogan O. High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study. J Dig Dis 2015;16:286-92. [PMID: 25708813 DOI: 10.1111/1751-2980.12237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
156 Zhang XX, Li MR, Cao Y, Zhang RW, Zhang Y, Li F, Xi HL, Xu XY. Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study. Medicine (Baltimore) 2016;95:e2614. [PMID: 26825915 DOI: 10.1097/MD.0000000000002614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Vivekanandan P, Singh OV. Molecular methods in the diagnosis and management of chronic hepatitis B. Expert Rev Mol Diagn 2010;10:921-35. [PMID: 20964611 DOI: 10.1586/erm.10.75] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
158 Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, Jiang J, Chen X, Long H, Tang H, Yu Y, Sheng J, Chen S, Niu J, Ren H, Shi J, Dou X, Wan M, Jiang J, Xie Q, Shi G, Ning Q, Chen C, Tan D, Ma H, Sun J, Jia J, Zhuang H, Hou J. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol 2015;30:748-55. [PMID: 25352300 DOI: 10.1111/jgh.12835] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
159 Gupta S, Altice FL. Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health 2009;86:263-79. [PMID: 19184447 DOI: 10.1007/s11524-008-9338-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
160 Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20:e37-e46. [PMID: 23490388 DOI: 10.1111/jvh.12025] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
161 Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009;9:256-264. [PMID: 19324298 DOI: 10.1016/s1473-3099(09)70056-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
162 Nguyen T, Locarnini S, Desmond P. Changing landscape of antiviral resistance management in chronic hepatitis B. J Gastroenterol Hepatol 2008;23:1314-7. [PMID: 18853991 DOI: 10.1111/j.1440-1746.2008.05551.x] [Reference Citation Analysis]
163 Wang C, Yu S, Zhang Y, Zhang M, Lv L, Huang C, Li X, Li J, Zhang Z. Viral quasispecies of hepatitis B virus in patients with YMDD mutation and lamivudine resistance may not predict the efficacy of lamivudine/adefovir rescue therapy. Exp Ther Med 2019;17:2473-84. [PMID: 30906435 DOI: 10.3892/etm.2019.7255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
164 Asselah T, Lada O, Moucari R, Marcellin P. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2008;17:1963-74. [DOI: 10.1517/13543780802535760] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
165 Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A, Thamm S, Zoulim F. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol. 2007;45:3948-3953. [PMID: 17942654 DOI: 10.1128/jcm.01180-07] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
166 Wang LC, Chen EQ, Zhu XF, Xiong ZH, Liu L, Xu L, Lei XZ, Liu C, Tang H. Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks. Gut Liver. 2011;5:478-485. [PMID: 22195247 DOI: 10.5009/gnl.2011.5.4.478] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145-1158. [PMID: 21978243 DOI: 10.1111/j.1365-2036.2011.04869.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
168 Janssen HL, Reijnders JG. Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us? J Hepatol. 2009;51:1-3. [PMID: 19443071 DOI: 10.1016/j.jhep.2009.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
169 Kim BK, Han K, Ahn SH. Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B. Digestion 2011;84:29-34. [DOI: 10.1159/000334076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
170 Xie QL, Zhu Y, Wu LH, Fu LL, Xiang Y. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. PLoS One. 2015;10:e0132219. [PMID: 26226455 DOI: 10.1371/journal.pone.0132219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
171 Hsu CW, Chen YC, Chang ML, Lin CC, Lin SM, Chen WT, Chu YD, Yeh CT. Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. Open Forum Infect Dis 2018;5:ofx271. [PMID: 29362723 DOI: 10.1093/ofid/ofx271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
172 Kao JH, Asselah T, Dou XG, Hamed K. Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model. J Gastroenterol Hepatol 2017;32:73-81. [PMID: 27515408 DOI: 10.1111/jgh.13512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
173 Zhu XF, Lu LX, Wang Y, Xu KW, Li DJ, Zhu X, Liu L, Liu C, Wang JR, Tang H. Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B. Hepat Mon. 2011;11:980-985. [PMID: 22368682 DOI: 10.5812/kowsar.1735143X.4203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
174 Ko SY, Choe WH, Kwon SY, Kim JH, Seo JW, Kim K, Lee CH. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scandinavian Journal of Gastroenterology 2012;47:1362-7. [DOI: 10.3109/00365521.2012.719927] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
175 Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int. 2008;2:304-307. [PMID: 19669258 DOI: 10.1007/s12072-008-9083-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
176 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56:2941-2947. [PMID: 22430972 DOI: 10.1128/aac.00338-12] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
177 Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Goodman Z, Philp FH, Tang Y, Locarnini S, Thio CL. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009;23:1707-1715. [PMID: 19584701 DOI: 10.1097/qad.0b013e32832b43f2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
178 Park H, Park JY, Kim SU, Kim DY, Han KH, Chon CY, Ahn SH. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol 2013; 19(43): 7671-7679 [PMID: 24431895 DOI: 10.3748/wjg.v19.i43.7671] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
179 Huang YJ, Chang CS, Peng YC, Yeh HZ, Yang SS. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS One 2017;12:e0174046. [PMID: 28350873 DOI: 10.1371/journal.pone.0174046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
180 Ismail AM, Sachithanandham J, Eapen CE, Kannangai R, Abraham P. Performance of LigAmp assay for sensitive detection of drug-resistant hepatitis B virus minor variants in comparison with standard nucleotide sequencing. Mol Diagn Ther 2014;18:655-63. [PMID: 25208639 DOI: 10.1007/s40291-014-0119-y] [Reference Citation Analysis]
181 Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008;22:1081-92. [PMID: 19187868 DOI: 10.1016/j.bpg.2008.11.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
182 Parusu T, Ponneri V. RP-HPLC method for simultaneous determination of atenolol and indapamide in pharmaceutical dosage forms, human blood and milk. Eur J Chem 2012;3:138-42. [DOI: 10.5155/eurjchem.3.2.138-142.537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
183 Law S, Lee MK, Li KK, Mok CK. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B: . European Journal of Gastroenterology & Hepatology 2016;28:193-8. [DOI: 10.1097/meg.0000000000000519] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
184 Hartono JL, Aung MO, Dan YY, Gowans M, Lim K, Lee YM, Lee GH, Low HC, Tan PS, Thwin MA, Soon C, Chiu L, Khoo MJ, Koay E, Lim SG. Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B. Aliment Pharmacol Ther 2013;37:710-9. [DOI: 10.1111/apt.12251] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
185 Lee HW, Kang W, Ahn SH, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Kim JK, Kim DY, Paik YH, Lee CK, Choi IS, Lee KS, Han KH. Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol 2014;29:1049-55. [PMID: 24575848 DOI: 10.1111/jgh.12522] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]